|
|
 |
| |
back
|
|
About Product
|
| 1. |
Product Name: |
Viread® Tab. 300mg |
| 2. |
Generic Name: |
Tenofovir Disoproxil Fumarate |
| 3. |
Indication: |
HIV-1 infection |
| 4. |
Dosage and Administration: |
In adults, "Viread® Tab. 300mg" should usually be administered orally at a dose of 300mg of tenofovir disoproxil fumarate (as 245mg of tenofovir disoproxil), once daily. "Viread® Tab. 300mg" should be used in combination with other antiretroviral agents. |
| 5. |
Contraindications: |
Patients with a previously demonstrated hypersensitivity to any of the components of the product |
| 6. |
Adverse Reactions: |
In three double blind clinical studies abroad, 379 (41.6%) of 912 cases received Viread presented adverse reactions through week 48. The common adverse reactions were nausea, diarrhea, asthenia, headache, abdominal pain, vomiting, and dizziness etc. The common adverse reactions were in relation to gastrointestinal system. The common laboratory abnormalities were CK increased, triglyceride increased, serum amylase increased, etc. Clinically significant adverse reactions, including kidney problems, severe renal impairment, pancreatitis and lactic acidosis, may occur. |
| 7. |
Packaging: |
Viread® Tab. 300mg, 30 tablets per bottle |
| 8. |
Price: |
¥2,111.90 per tablet |
| 9. |
Date of NHI Price Listing: |
April 2, 2004 |
| 10. |
Imported by: |
Japan Tobacco Inc. |
| 11. |
Distributed by: |
Torii Pharmaceutical Co., Ltd. |
| 12. |
Supplied by: |
Gilead Sciences Inc. |
|
|
|
|
| |
|
|
|
|
